Overview

Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Status:
Completed

Trial end date:
2019-11-25

Target enrollment:

Participant gender:

Summary

CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in patients of African ancestry and non-African ancestry with advanced triple negative breast cancer. Multiple single-arm cohorts will be enrolled in which 800 mg twice daily (BID) CB-839 will be administered in combination with the full approved dose of paclitaxel.

Phase:

Phase 2

Details

Lead Sponsor:

Calithera Biosciences, Inc

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel
Taxane